Evidence map›Paper›PMID 25896974›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Xiangqian Guo, Vickie Y Jo, Anne M Mills, Shirley X Zhu, Cheng-Han Lee, Inigo Espinosa, Marisa R Nucci, Sushama Varma, Erna Forgó, Trevor Hastie and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Transcriptomic Subgroups in Soft Tissue Tumors Correlate with Morphologic Subtype, Genomic Features, and Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Xiangqian GuoDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Vickie Y JoDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Anne M MillsDepartment of Pathology, University of Virginia, Charlottesville, Virginia.
Shirley X ZhuDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Cheng-Han LeeDivision of Anatomical Pathology, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Inigo EspinosaDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Marisa R NucciDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Sushama VarmaDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Erna ForgóDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Trevor HastieDepartment of Statistics, Stanford University, Stanford, California.
Sharon AndersonDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Kristen GanjooStanford Comprehensive Cancer Center, Stanford University, Stanford, California.
Andrew H BeckDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Robert B WestDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Christopher D FletcherDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Matt van de RijnDepartment of Pathology, Stanford University School of Medicine, Stanford, California. mrijn@stanford.edu.
Brigham and Women's Hospital · US

Funding

Molecular Characterization of Leiomyosarcoma and GISTR01CA112270 · NCI · STANFORD UNIVERSITY · PI VAN DE RIJN, JAN MATT · 2005 to 2014
$3.0M
NCI NIH HHS CA 112270NCI NIH HHS R01 CA112270
6 · The paper itself

Abstract

purposeLeiomyosarcoma is a malignant neoplasm with smooth muscle differentiation. Little is known about its molecular heterogeneity and no targeted therapy currently exists for leiomyosarcoma. Recognition of different molecular subtypes is necessary to evaluate novel therapeutic options. In a previous study on 51 leiomyosarcomas, we identified three molecular subtypes in leiomyosarcoma. The current study was performed to determine whether the existence of these subtypes could be confirmed in independent cohorts. EXPERIMENTAL

designNinety-nine cases of leiomyosarcoma were expression profiled with 3'end RNA-Sequencing (3SEQ). Consensus clustering was conducted to determine the optimal number of subtypes.

resultsWe identified 3 leiomyosarcoma molecular subtypes and confirmed this finding by analyzing publically available data on 82 leiomyosarcoma from The Cancer Genome Atlas (TCGA). We identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers; LMOD1 for subtype I leiomyosarcoma and ARL4C for subtype II leiomyosarcoma. A leiomyosarcoma tissue microarray with known clinical outcome was used to show that subtype I leiomyosarcoma is associated with good outcome in extrauterine leiomyosarcoma while subtype II leiomyosarcoma is associated with poor prognosis in both uterine and extrauterine leiomyosarcoma. The leiomyosarcoma subtypes showed significant differences in expression levels for genes for which novel targeted therapies are being developed, suggesting that leiomyosarcoma subtypes may respond differentially to these targeted therapies.

conclusionsWe confirm the existence of 3 molecular subtypes in leiomyosarcoma using two independent datasets and show that the different molecular subtypes are associated with distinct clinical outcomes. The findings offer an opportunity for treating leiomyosarcoma in a subtype-specific targeted approach.

Indexed as

PrognosisAdolescentAdultAgedAged, 80 and overBiomarkers, TumorChildChild, PreschoolFemaleGene Expression Regulation, NeoplasticHumansLeiomyosarcomaMaleMiddle AgedNeoplasm ProteinsOligonucleotide Array Sequence AnalysisBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID25896974
PMCPMC4526352
OpenAlexW1987085807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.